Horizon Technology Finance Provides Investment Portfolio

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Technology Finance Provides Investment Portfolio Update for Fourth Quarter 2013

FARMINGTON, Conn., Jan. 8, 2014 (GLOBE NEWSWIRE) -- Horizon Technology Finance Corporation (Nasdaq: HRZN ) ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today provided a portfolio update for the fourth quarter of 2013.

"We experienced a notable increase in investment activity during the fourth quarter as compared to the prior quarter, as we added eight loans to our portfolio and increased our committed backlog to $19 million," said Gerald A. Michaud, President of Horizon. "We also continued to benefit from the dynamic nature of our venture loan portfolio based on successful liquidity events from four portfolio companies in the quarter, including one that was on non-accrual. As a result of our ongoing efforts, we believe the overall quality of our current investment portfolio is strong and we remain focused on efficiently deploying capital into high yielding loan assets and creating opportunities to monetize our warrant portfolio."

New Loans Funded

New loans funded during the fourth quarter of 2013 totaled $19.0 million. During the fourth quarter of 2013, Horizon provided funding to the following new and existing portfolio companies:

  • $6.0 million to a new portfolio company, Mederi Therapeutics, Inc., a developer of minimally invasive treatments for gastroesophageal reflux disease and bowel control disorder.
  • $3.0 million to a new portfolio company, VBrick Systems, Inc., a provider of enterprise IP video platforms.
  • $2.5 million to an existing portfolio company, Avalanche Technology, Inc., a developer of next-generation storage products utilizing its proprietary Spin Programmable Memory technology.
  • $2.5 million to an existing portfolio company, a provider of Carrier Ethernet solutions for communications service providers and network operators.
  • $2.5 million to an existing portfolio company, Recondo Technology, a software company that develops cloud computing solutions throughout the healthcare revenue cycle.
  • $1.0 million to a new portfolio company, Nanocomp Technologies, Inc., a developer of high performance materials and component products made from carbon nanotubes.
  • $1.0 million to an existing portfolio company, a provider of cloud-based financial assurance and predictive analytics solutions for communications service providers.
  • $0.5 million to an existing portfolio company, Ekahau, Inc., a provider of RFID-over-Wi-Fi™ Real-Time Location Systems which enables enterprises to locate, track and manage assets, inventory, staff and visitors.

Liquidity Events

During the quarter ended December 31, 2013, Horizon experienced liquidity events from four portfolio companies, increasing the total number of liquidity events to 11 for the year ended December 31, 2013. Liquidity events for Horizon may consist of the exercise of warrants in portfolio companies, loan prepayments or receipt of success fees.

As previously reported, IBM acquired Fiberlink Communications Corporation ("Fiberlink"), a portfolio company of Horizon. In connection with the acquisition, Fiberlink prepaid its principal loan balance of $8.0 million and paid Horizon a success fee of $0.4 million, a final payment and a prepayment fee. As a result, Horizon's fully realized internal rate of return was 25.2% on its investment in Fiberlink.

In November, Direct Flow Medical, Inc. ("Direct Flow") prepaid the outstanding principal balance of its $7.5 million venture loan from Horizon, and paid all outstanding interest, a final payment and a prepayment fee. Horizon continues to hold warrants in Direct Flow. With the prepayment, Horizon's current realized internal rate of return on its investment in Direct Flow is 17.8%, with the potential for additional returns from warrant gains.

Also in November, Celsion Corporation ("Celsion") prepaid the outstanding principal balance of its loan in the approximate amount of $2.0 million, together with a prepayment fee. Horizon continues to hold warrants in Celsion. Horizon's realized internal rate of return on its investment in Celsion is currently 13.6% with the opportunity for additional returns from warrant gains in the future.

As previously announced, Horizon settled its outstanding loan to ACT Biotech, Inc. ("ACT") in connection with the sale of substantially all of the assets of ACT to a private venture capital-backed biotechnology company. In connection with this transaction, Horizon received a cash payment of approximately $2.1 million as well as the right to receive up to $17 million in contingent contractual success payments. Horizon continues to hold warrants in ACT. Horizon expects to record a realized loss on its loan to ACT, which was on non-accrual as of September 30, 2013, of approximately $1.9 million for the quarter ended December 31, 2013. Horizon had previously recorded unrealized depreciation of $1.2 million of this $1.9 million in prior periods.

Refinanced Principal Balances, Early Principal Payoffs, and Principal Payments Received

During the quarter ended December 31, 2013, Horizon did not refinance any principal balances. Horizon experienced early pay-offs totaling $19.6 million, compared to early pay-offs of principal totaling $7.5 million during the third quarter of 2013. During the quarter ended December 31, 2013, Horizon received regularly scheduled principal payments on investments totaling $12 million compared to the quarter ended September 30, 2013, wherein Horizon received regularly scheduled principal payments on investments totaling $10.5 million.

Commitments

During the quarter ended December 31, 2013, Horizon closed new loan commitments totaling approximately $21.0 million to six companies, compared to the quarter ended September 30, 2013, wherein Horizon closed new loan commitments totaling $8.0 million to three companies.

Pipeline

As of December 31, 2013, Horizon's unfunded loan approvals and commitments ("Committed Backlog") were $19.0 million to five companies, compared to a Committed Backlog of $11.5 million to seven companies as of September 30, 2013. While Horizon's portfolio companies have discretion whether to draw down such commitments, in some cases, the right of a company to draw down its commitment is subject to the portfolio company achieving specific milestones.

About Horizon Technology Finance

Horizon Technology Finance Corporation is a business development company that provides secured loans to development-stage companies backed by established venture capital and private equity firms within the technology, life science, healthcare information and services, and clean-tech industries. The investment objective of Horizon is to maximize total risk-adjusted returns by generating current income from a portfolio of directly originated secured loans as well as capital appreciation from warrants to purchase the equity of portfolio companies. Headquartered in Farmington, Connecticut, with regional offices in Walnut Creek, California and Reston, Virginia, Horizon is externally managed by its investment advisor, Horizon Technology Finance Management LLC. Horizon's common stock trades on the NASDAQ Global Select Market under the ticker symbol "HRZN." In addition, Horizon's 7.375% Senior Notes due 2019 trade on the New York Stock Exchange under the ticker symbol "HTF." To learn more, please visit www.horizontechnologyfinancecorp.com .

Forward-Looking Statements

Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. Horizon undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Horizon Technology Finance Corporation Christopher M. Mathieu Chief Financial Officer (860) 676-8653 Investor Relations and Media Contacts: The IGB Group Michael Cimini / Leon Berman (212) 477-8261 / (212) 477-8438 /

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 266

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 33

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 0

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Precious Metals and Energy Investors' Strategies

Updated Category News Views 143

Current Trends in Precious Metals The appeal of precious metals like gold and silver continues to gather momentum, particularly in light of recent global events. Many analysts believe that geopolitical tensions have created a catalyst for increased interest in gold as a safe haven. As governments grapple with economic challenges, investors are keenly observing changes in...

Continue Reading
Understanding P/E Ratios in the Context of Casey's General Stores

Updated Category News Views 175

Analyzing P/E Ratios for Investment Decisions In today’s market, understanding the performance metrics of stocks is vital. Currently, Casey's General Stores Inc. (NASDAQ: CASY) is noted at an impressive share price of $536.66. This reflects a modest increase of 0.33%. In examining market trends, the past month saw a slight decline of 4.39% in share value. However,...

Continue Reading
China's New Lending Outlook: Economic Recovery Strategies

Updated Category News Views 135

China's Recent New Lending Trends Recent updates reveal a significant rise in new bank lending in China. However, it didn't quite meet expectations, as analysts had hoped for a stronger performance. After disappointing figures in July, which hit a 15-year low, new data shows that Chinese banks issued around 900 billion yuan (approximately $126.86 billion) in new loans in...

Continue Reading
ParkOhio Shares Important Quarterly Dividend News for Investors

Updated Category News Views 177

ParkOhio Holdings Announces Latest Dividend Declaration Park-Ohio Holdings Corp. (NASDAQ: PKOH) recently declared a significant quarterly cash dividend of $0.125 per share to its common stockholders. This distribution demonstrates the company's ongoing commitment to providing returns to its shareholders. This dividend will be payable soon, marking another positive...

Continue Reading
Investigation Launched for Tourmaline Bio's Shareholders

Updated Category News Views 259

Investigation Overview on Tourmaline Bio, Inc. Recently, Monteverde & Associates PC, a renowned law firm, has initiated an investigation concerning Tourmaline Bio, Inc. (NASDAQ: TRML) and its proposed sale to Novartis AG. This potential acquisition raises several questions about the fairness of the deal, specifically regarding the cash payment offered to shareholders....

Continue Reading